No connection

Search Results

GKOS vs JNJ

GKOS
Glaukos Corporation
NEUTRAL
Price
$122.07
Market Cap
$7.14B
Sector
Healthcare
AI Confidence
80%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GKOS
--
JNJ
21.55
Forward P/E
GKOS
282.75
JNJ
18.9
P/B Ratio
GKOS
10.7
JNJ
7.03
P/S Ratio
GKOS
14.08
JNJ
6.09
EV/EBITDA
GKOS
-142.15
JNJ
17.81

Profitability

Gross Margin
GKOS
77.96%
JNJ
68.08%
Operating Margin
GKOS
-18.87%
JNJ
23.97%
Profit Margin
GKOS
-36.99%
JNJ
28.46%
ROE
GKOS
-26.38%
JNJ
35.03%
ROA
GKOS
-5.8%
JNJ
8.68%

Growth

Revenue Growth
GKOS
35.7%
JNJ
9.1%
Earnings Growth
GKOS
--
JNJ
48.6%

Financial Health

Debt/Equity
GKOS
0.16
JNJ
0.6
Current Ratio
GKOS
4.69
JNJ
1.03
Quick Ratio
GKOS
3.83
JNJ
0.69

Dividends

Dividend Yield
GKOS
--
JNJ
2.19%
Payout Ratio
GKOS
0.0%
JNJ
46.6%

AI Verdict

GKOS NEUTRAL

GKOS presents a dichotomy between strong operational growth and extreme valuation. The Piotroski F-Score of 5/9 indicates a stable financial foundation, supported by an exceptional current ratio of 4.69 and very low debt/equity (0.16). However, the company remains unprofitable with a negative profit margin of -36.99% and a staggering forward P/E of 282.75. While revenue growth is robust at 35.7%, the bearish insider sentiment and weak technical trend suggest a disconnect between analyst optimism and internal confidence.

Strengths
Strong revenue growth (35.7% YoY)
Excellent liquidity with a current ratio of 4.69
High gross margins (77.96%) indicating strong product pricing power
Risks
Extreme valuation metrics (Forward P/E 282.75, P/S 14.08)
Persistent lack of profitability over 25 consecutive quarters
Bearish insider activity with $6.41M in sales and zero buys
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

GKOS vs JNJ: Head-to-Head Comparison

This page compares Glaukos Corporation (GKOS) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile